Compare Bristol-Myers Squibb Co (BMY) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Ecopetrol SA — how do they compare? Bristol-Myers Squibb Co trades at $58.82 (market cap $116.30B), while Ecopetrol SA trades at $16.03 (market cap $29.46B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.9× Ecopetrol SA's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | EC | |
|---|---|---|
Market Cap | $116.30B | $29.46B |
Sector | Health | Energy |
52-Week High | $62.37 | $16.58 |
52-Week Low | $42.60 | $8.29 |
Enterprise Value | $152.24B | $57.24B |
Dividend Yield | 4.42% | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Ecopetrol (EC) trades at $15.88, up 1.93% with a bullish technical signal from moving averages. The stock shows mixed earnings performance with recent misses but maintains solid profitability with 8.76% net margin and 13.01% ROE. Recent positive developments include a collective bargaining agreement with workers and S&P credit rating affirmation. Valuation appears reasonable with P/E of 11.31 and P/S of 0.99, trading near analyst consensus target of $14.63.
EC presents a balanced opportunity with attractive valuation metrics and stable dividend yield, though facing revenue decline from $159.6B in 2022 to $119.7B in 2025. Key risks include ongoing revenue pressure, debt levels at 42.51% of assets, and oil price volatility. Analyst sentiment is cautious with 27% buy ratings versus 55% hold, suggesting limited near-term upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
